Ruiz I, Pawlotsky Jean-Michel

Language: English
References: 14
Page: 179-181
PDF size: 118.57 Kb.

Text Extraction

Hepatitis B reactivation or hepatitis C exacerbation are critical clinical problems in patients with hematological malignancies undergoing immunosuppressive therapy or chemotherapy. Indeed, they can cause acute liver failure that may, in turn, delay or interrupt chemotherapy with a dramatic impact on cancer evolution. Risk factors for hepatitis B virus (HBV) reactivation have been described in patients receiving chemotherapy, including male gender, older age, chemotherapy regimen (monoclonal antibodies such as rituximab, ofatumumab, obinutumumab) and hepatitis B status (presence of hepatitis B surface antigen [HBsAg] or of isolated antibodies directed against the HBV core protein [anti-HBc antibodies]). Screening all patients with hematological malignancies for HBsAg and anti-HBc antibodies is thus key to prevent HBV reactivation. 3 International clinical practice guidelines recommend pre-emptive/prophylactic therapy in patients with hematological malignancies and HBV markers who receive chemotherapy.

REFERENCES

1. Castelli R, Ferraris L, Pantaleo G, Lambertenghi-Deliliers G, Cicardi M. High rate of hepatitis B viral breakthrough in elderly non-Hodgkin lymphomas patients treated with Rituximab based chemotherapy. Dig Liver Dis 2016; 48: 1394-7.

2. Ozoya OO, Sokol L, Dalia S. Hepatitis B Reactivation with novel agents in non-Hodgkin’s lymphoma and prevention strategies. J Clin Transl Hepatol 2016; 4(2): 143-50.

3. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015; 61(2): 703-11.

4. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57(1): 167-85.

5. Visram A, Feld JJ. Defining and grading HBV reactivation. Clinical Liver Disease 2015; 5(2): 35-8.

6. Mahale P, Kontoyiannis DP, Chemaly RF, Jiang Y, Hwang JP, Davila M, Torres HA. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol 2012; 57: 1177-85.

7. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 2017; 66(1): 153-94.

8. Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, Wu X, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large Bcell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA 2014; 312: 2521-30.

9. Liu Z, Jiang L, Liang G, Song E, Zheng Y, Gong C. Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: a review and meta-analysis of prophylaxis management. J Viral Hepat 2017; 00: 1-12.doi: 10.1111/ jvh.12672.

10. Cerva C, Colagrossi L, Maffongelli G, Salpini R, Di Carlo D, Malagnino V, Battisti A, et al. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor. Clin Microbiol Infect 2016; 22: 946.e1-946.e8.

11. Tseng CM, Chen TB, Hsu YC, Chang CY, Lin JT, Mo LR. Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy. Asia Pac J Clin Oncol 2016; 12(4): 421-9.

12. Zhang MY, Zhu GQ, Shi KQ, Zheng JN, Cheng Z, Zou ZL, Huang HH, et al. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. Oncotarget 2016; 7: 30642-58.

13. De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol 2016; 119: 1-7.

14. Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, Flaherty JF, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol 2015; 62: 533-40.